<?xml version='1.0' encoding='utf-8'?>
<document id="29749631"><sentence text="Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety."><entity charOffset="17-29" id="DDI-PubMed.29749631.s1.e0" text="Posaconazole" /><entity charOffset="66-76" id="DDI-PubMed.29749631.s1.e1" text="Ranolazine" /><entity charOffset="96-108" id="DDI-PubMed.29749631.s1.e2" text="Posaconazole" /><pair ddi="false" e1="DDI-PubMed.29749631.s1.e0" e2="DDI-PubMed.29749631.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s1.e0" e2="DDI-PubMed.29749631.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s1.e0" e2="DDI-PubMed.29749631.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29749631.s1.e1" e2="DDI-PubMed.29749631.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s1.e1" e2="DDI-PubMed.29749631.s1.e2" /></sentence><sentence text="The antianginal agent ranolazine (Ranexa®) is metabolized primarily by cytochrome P450-3A (CYP3A) enzymes"><entity charOffset="22-32" id="DDI-PubMed.29749631.s2.e0" text="ranolazine" /></sentence><sentence text=" Coadministration with strong CYP3A inhibitors, such as ketoconazole and posaconazole, is contraindicated due to risk of QT prolongation from high levels of ranolazine"><entity charOffset="56-68" id="DDI-PubMed.29749631.s3.e0" text="ketoconazole" /><entity charOffset="73-85" id="DDI-PubMed.29749631.s3.e1" text="posaconazole" /><entity charOffset="157-167" id="DDI-PubMed.29749631.s3.e2" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.29749631.s3.e0" e2="DDI-PubMed.29749631.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s3.e0" e2="DDI-PubMed.29749631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s3.e0" e2="DDI-PubMed.29749631.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29749631.s3.e1" e2="DDI-PubMed.29749631.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s3.e1" e2="DDI-PubMed.29749631.s3.e2" /></sentence><sentence text=" This study evaluated the time course of recovery from the posaconazole drug interaction in normal-weight and otherwise healthy obese subjects"><entity charOffset="59-71" id="DDI-PubMed.29749631.s4.e0" text="posaconazole" /></sentence><sentence text=" Subjects received single doses of ranolazine in the baseline control condition, again during coadministration of posaconazole, and at 4 additional time points during the 2 weeks after posaconazole discontinuation"><entity charOffset="35-45" id="DDI-PubMed.29749631.s5.e0" text="ranolazine" /><entity charOffset="114-126" id="DDI-PubMed.29749631.s5.e1" text="posaconazole" /><entity charOffset="185-197" id="DDI-PubMed.29749631.s5.e2" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.29749631.s5.e0" e2="DDI-PubMed.29749631.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s5.e0" e2="DDI-PubMed.29749631.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s5.e0" e2="DDI-PubMed.29749631.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29749631.s5.e1" e2="DDI-PubMed.29749631.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29749631.s5.e1" e2="DDI-PubMed.29749631.s5.e2" /></sentence><sentence text=" With posaconazole coadministration, the geometric mean ratio of ranolazine area under the concentration curve (AUC) increased by a factor of 3"><entity charOffset="6-18" id="DDI-PubMed.29749631.s6.e0" text="posaconazole" /><entity charOffset="65-75" id="DDI-PubMed.29749631.s6.e1" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.29749631.s6.e0" e2="DDI-PubMed.29749631.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s6.e0" e2="DDI-PubMed.29749631.s6.e1" /></sentence><sentence text="9 in normals and by 2" /><sentence text="8 in obese subjects" /><sentence text=" Posttreatment washout of posaconazole was slow in normals (mean half-life 36 hours) and further prolonged in obese subjects (64 hours)"><entity charOffset="26-38" id="DDI-PubMed.29749631.s9.e0" text="posaconazole" /></sentence><sentence text=" Recovery of ranolazine AUC toward baseline was delayed"><entity charOffset="13-23" id="DDI-PubMed.29749631.s10.e0" text="ranolazine" /></sentence><sentence text=" AUC remained significantly elevated above baseline in normal-weight and obese subjects for 7-14 days after stopping posaconazole"><entity charOffset="117-129" id="DDI-PubMed.29749631.s11.e0" text="posaconazole" /></sentence><sentence text=" Current product labeling does not address the need for delay or a reduced dose of ranolazine after discontinuation of a strong CYP3A inhibitor before ranolazine can be safely administered"><entity charOffset="83-93" id="DDI-PubMed.29749631.s12.e0" text="ranolazine" /><entity charOffset="151-161" id="DDI-PubMed.29749631.s12.e1" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.29749631.s12.e0" e2="DDI-PubMed.29749631.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s12.e0" e2="DDI-PubMed.29749631.s12.e1" /></sentence><sentence text=" We recommend that administration of ranolazine should be limited to 500 mg twice daily for 7 days after posaconazole discontinuation in patients with body mass index 18"><entity charOffset="37-47" id="DDI-PubMed.29749631.s13.e0" text="ranolazine" /><entity charOffset="105-117" id="DDI-PubMed.29749631.s13.e1" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.29749631.s13.e0" e2="DDI-PubMed.29749631.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29749631.s13.e0" e2="DDI-PubMed.29749631.s13.e1" /></sentence><sentence text="5-24" /><sentence text="9 kg/m2 and for 12 days in patients with body mass index ≥35 kg/m2 after ranolazine is resumed"><entity charOffset="73-83" id="DDI-PubMed.29749631.s15.e0" text="ranolazine" /></sentence><sentence text="" /></document>